GEN Exclusives

More »

GEN News Highlights

More »
Apr 16, 2007

Ciphergen Implicates Four Proteins in Early-Stage Ovarian Cancer

  • Ciphergen Biosystems report that it has discovered four proteins that may be potential diagnostic markers for early-stage ovarian cancer. Along with collaborators, the researchers say that these four proteins in urine separate women with early cancer from healthy individuals with a sensitivity of 56% and a specificity of 95%.

    To elucidate these findings, Ciphergen employed protein expression profiling methods to analyze urine samples from 400 women, including 288 women with epithelial ovarian cancer, 52 with early-stage disease, and 176 with late-stage disease, 74 women with benign ovarian disease, and 98 normal, healthy controls.

    "By demonstrating that these findings are reproducible, Ciphergen hopes to advance these markers beyond the clinical validation process and into clinical trials," says Eric T. Fung, M.D., Ph.D., CSO.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Tackling the Global Problem of Fake Medicines

Policy proposals to address the growing global problem of fake medicines include a global agreement, similar to the Framework Convention on Tobacco Control, and stricter national laws to prosecute those who knowingly sell counterfeit medicines. Do you think these steps will be successful?

More »